Abstract
The study by James P Buteau and colleagues1 published in The Lancet Oncology is well written and clear. This particular analysis of the TheraP trial of lutetium-177 [177Lu]Lu-PSMA-617 versus cabazitaxel in men with metastatic castration-resistant prostate cancer focused on prespecified tertiary endpoints using quantitative PET parameters and various outcomes, including prostate-specific antigen (PSA) response, radiographic progression-free survival, and PSA progression-free survival.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
